Page 8 - HIV/AIDS Guidelines

Appendix B, Table 4. Characteristics of Integrase Inhibitor.....................................................O-11

Appendix B, Table 5. Characteristics of Fusion Inhibitor.........................................................O-11
Appendix B, Table 6. Characteristics of CCR5 Antagonist......................................................O-12
Appendix B, Table 7. Antiretroviral Dosing Recommendations in
Patients with Renal or Hepatic Insufficiency............................................................................O-13

Appendix C: Monthly Average Wholesale Price of Antiretroviral Drugs...................................P-1

List of Tables
Table 1. Outline of the Guidelines Development Process ..........................................................A-2
Table 2. Rating Scheme for Recommendations..........................................................................A-3

Table 3. Laboratory Monitoring Schedule for Patients Prior to and After Initiation
of Antiretroviral Therapy ............................................................................................................C-2

Table 4. Recommendations for Using Drug-Resistance Assays ...............................................C-12
Table 5a. Preferred and Alternative Antiretroviral Regimens for
Antiretroviral Therapy-Naive Patients ........................................................................................F-3
Table 5b. Acceptable Antiretroviral Regimens for Treatment-Naive Patients ............................F-4
Table 6. Advantages and Disadvantages of Antiretroviral Components
Recommended as Initial Antiretroviral Therapy .......................................................................F-16
Table 7. Antiretroviral Components Not Recommended as Initial Therapy .............................F-20
Table 8. Antiretroviral Regimens or Components That Should Not Be Offered At Any Time ..G-3
Table 9a. Trough Concentrations of Antiretroviral Drugs for Patients
Who Have Drug-Susceptible Virus...........................................................................................H-17
Table 9b. Trough Concentrations of Antiretroviral Drugs for
Treatment-Experienced Patients with Virologic Failure...........................................................H-18
Table 10. Identifying, Diagnosing, and Managing Acute HIV-1 Infection ..................................I-4
Table 11. Drug Interactions between Antiretroviral Agents and Drugs
Used to Treat Opioid Addiction..................................................................................................I-14
Table 12. Strategies to Improve Adherence to Antiretroviral Therapy .......................................K-4
Table 13. Antiretroviral Therapy-Associated Common and/or Severe Adverse Effects.............K-8

Table 14. Drugs That Should Not Be Used with PIs, NNRTIs, or CCR5 Antagonist ..............K-17
Table 15a. Drug Interactions between PIs and Other Drugs.....................................................K-19
Table 15b. Drug Interactions between NNRTIs and Other Drugs ............................................K-30
Table 15c. Drug Interactions between NRTIs and Other Drugs (Including ARV Agents) .......K-36

Table 15d. Drug Interactions between CCR5 Antagonist and Other Drugs .............................K-38
Table 15e. Drug Interactions between Integrase Inhibitor and Other Drugs ............................K-39
Table 16a. Interactions among PIs ............................................................................................K-40
Table 16b. Interactions between NNRTIs, MVC, RAL, and PIs..............................................K-41

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents vi

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.